153 related articles for article (PubMed ID: 9506349)
21. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors.
Tutar N; Yetkin NA; Yazıcı C; Önal Ö; Kontaş O; Keleştemur F
Turk J Med Sci; 2019 Jun; 49(3):774-781. PubMed ID: 31091854
[TBL] [Abstract][Full Text] [Related]
23. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
24. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
25. Cross-Sectional Study to Establish the Utility of Serum Tumor Markers in the Diagnosis of Lung Cancer.
Mehta A; Parkash A; Bhatia M
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2569-2576. PubMed ID: 34452572
[TBL] [Abstract][Full Text] [Related]
26. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
27. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer.
Oh HJ; Park HY; Kim KH; Park CK; Shin HJ; Lim JH; Kwon YS; Oh IJ; Kim YI; Lim SC; Kim YC; Kim SH; Shin MG
J Thorac Dis; 2016 Sep; 8(9):2530-2537. PubMed ID: 27747005
[TBL] [Abstract][Full Text] [Related]
28. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
29. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
30. Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor marker for small-cell lung carcinoma: development and evaluation.
Aoyagi K; Miyake Y; Urakami K; Kashiwakuma T; Hasegawa A; Kodama T; Yamaguchi K
Clin Chem; 1995 Apr; 41(4):537-43. PubMed ID: 7720242
[TBL] [Abstract][Full Text] [Related]
31. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
[TBL] [Abstract][Full Text] [Related]
32. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
[TBL] [Abstract][Full Text] [Related]
33. Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension.
Okada M; Sakamoto T; Nishio W; Uchino K; Tsubota N
Cancer; 2003 Aug; 98(3):535-41. PubMed ID: 12879471
[TBL] [Abstract][Full Text] [Related]
34. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
[TBL] [Abstract][Full Text] [Related]
35. Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma.
Nagakawa O; Furuya Y; Fujiuchi Y; Fuse H
Urology; 2002 Sep; 60(3):527-30. PubMed ID: 12350511
[TBL] [Abstract][Full Text] [Related]
36. Automated time-resolved immunofluorometric assay for progastrin-releasing peptide.
Nordlund MS; Warren DJ; Nustad K; Bjerner J; Paus E
Clin Chem; 2008 May; 54(5):919-22. PubMed ID: 18443179
[TBL] [Abstract][Full Text] [Related]
37. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
Huang Z; Xu D; Zhang F; Ying Y; Song L
Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
[TBL] [Abstract][Full Text] [Related]
38. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
39. Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma.
Ameshima S; Ishizaki T; Demura Y; Imamura Y; Miyamori I; Mitsuhashi H
Cancer; 2000 Oct; 89(7):1448-56. PubMed ID: 11013357
[TBL] [Abstract][Full Text] [Related]
40. Elevated progastrin-releasing peptide(31-98) concentrations in pleural effusions due to small-cell lung carcinoma.
Shijubo N; Hirasawa M; Sasaki H; Igarashi T; Fujita A; Kodama T; Yamaguchi K; Abe S
Respiration; 1996; 63(2):106-10. PubMed ID: 8966363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
